Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus the development activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids).
The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome.
The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease.